KR20220047775A - 인간 피험자의 조직에서 에테르 지질 분자의 혼합물을 유지 또는 조절하기 위한 조성물 - Google Patents

인간 피험자의 조직에서 에테르 지질 분자의 혼합물을 유지 또는 조절하기 위한 조성물 Download PDF

Info

Publication number
KR20220047775A
KR20220047775A KR1020227005189A KR20227005189A KR20220047775A KR 20220047775 A KR20220047775 A KR 20220047775A KR 1020227005189 A KR1020227005189 A KR 1020227005189A KR 20227005189 A KR20227005189 A KR 20227005189A KR 20220047775 A KR20220047775 A KR 20220047775A
Authority
KR
South Korea
Prior art keywords
ether
composition
lipid
groups
ether lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227005189A
Other languages
English (en)
Korean (ko)
Inventor
피터 존 메이클
Original Assignee
베이커 하트 앤드 다이어비티스 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902527A external-priority patent/AU2019902527A0/en
Application filed by 베이커 하트 앤드 다이어비티스 인스티튜트 filed Critical 베이커 하트 앤드 다이어비티스 인스티튜트
Publication of KR20220047775A publication Critical patent/KR20220047775A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pediatric Medicine (AREA)
  • Birds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020227005189A 2019-07-17 2020-07-17 인간 피험자의 조직에서 에테르 지질 분자의 혼합물을 유지 또는 조절하기 위한 조성물 Pending KR20220047775A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902527 2019-07-17
AU2019902527A AU2019902527A0 (en) 2019-07-17 Compositions and methods of use
PCT/AU2020/050742 WO2021007623A1 (en) 2019-07-17 2020-07-17 Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject

Publications (1)

Publication Number Publication Date
KR20220047775A true KR20220047775A (ko) 2022-04-19

Family

ID=74209622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005189A Pending KR20220047775A (ko) 2019-07-17 2020-07-17 인간 피험자의 조직에서 에테르 지질 분자의 혼합물을 유지 또는 조절하기 위한 조성물

Country Status (10)

Country Link
US (1) US20220257616A1 (cg-RX-API-DMAC10.html)
EP (1) EP3999044A4 (cg-RX-API-DMAC10.html)
JP (1) JP7890196B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220047775A (cg-RX-API-DMAC10.html)
CN (2) CN120360984A (cg-RX-API-DMAC10.html)
BR (1) BR112022000814A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147249A1 (cg-RX-API-DMAC10.html)
IL (1) IL289859A (cg-RX-API-DMAC10.html)
MX (1) MX2022000664A (cg-RX-API-DMAC10.html)
WO (1) WO2021007623A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115236170B (zh) * 2022-07-25 2024-11-26 清华大学 基于毛细管电泳的脂质组分析系统及其应用和脂质组的分析方法
WO2024148052A1 (en) 2023-01-03 2024-07-11 Baker Heart and Diabetes Institute Ether of phosphatidylcholine and phosphatidylethanolamine, their lyso-forms and mixture thereof for use in the treatment of treatment of a disease or disorder caused by a deficiency in plasmalogens
EP4661856A1 (en) * 2023-02-10 2025-12-17 Baker Heart and Diabetes Institute Plasmalogen modulation of immune cells
WO2026008605A2 (en) 2024-07-01 2026-01-08 Pelagic Ai Limited Chemical synthesis of bioactive precursors to plasmalogens
WO2026008716A1 (en) 2024-07-02 2026-01-08 Baker Heart and Diabetes Institute Methods of use for plasmalogen precursors in treating plasmalogen-associated diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1029610A (en) 1965-04-08 1966-05-18 Shell Int Research Improvements in or relating to ethers
US4046914A (en) 1966-12-16 1977-09-06 Astra Nutrition Ab Therapeutically active substituted saturated and mono-and polyunsaturated alkyl-glycerylethers
JPS56133281A (en) 1980-03-21 1981-10-19 Kao Corp Preparation of glyceryl ether
US4613621A (en) 1981-09-18 1986-09-23 Hoerrmann Wilhelm Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases
US4595681A (en) * 1984-10-26 1986-06-17 The United States Of America As Represented By The United States Department Of Energy Antihypertensive neutral lipid
SE8800182L (sv) 1988-01-21 1989-07-22 Kaernerud Lars Haelsoprod Anvaendning av alkylglycerol foer framstaellning av ett laekemedel
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US20070191495A1 (en) 2004-01-16 2007-08-16 Fuji Oil Company, Limited Lipase inhibitor
FR2874156B1 (fr) 2004-08-13 2007-04-06 Univ Rennes 1 Etablissement Pu Complement alimentaire pour animaux d'elevage et procede de mise en oeuvre de celui-ci
US20090131368A1 (en) 2006-07-19 2009-05-21 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
EP2064544A1 (en) 2006-09-14 2009-06-03 Zora Biosciences OY Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
WO2009050692A2 (en) * 2007-10-16 2009-04-23 Vascular Biogenics Ltd. Platelet-activating factor (paf) analogs and uses thereof
US8975299B2 (en) 2007-11-01 2015-03-10 Enzymotec Ltd. Lipid mixture for infant nutrition
EP2403491A2 (en) 2009-03-04 2012-01-11 Nestec S.A. Alkylglycerols and alkoxyglycerols for increasing endogenous plasmalogen levels in mammals
FR2945951B1 (fr) 2009-05-26 2012-07-13 Polaris Composition d'akg et son utilisation pour la fabrication d'un medicament.
DE102009022907A1 (de) * 2009-05-27 2010-12-09 Kdg Mediatech Ag Optischer Datenträger
EP2309276A1 (en) 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
KR101787618B1 (ko) 2010-09-24 2017-10-18 후지노 브레인 리서치 가부시키가이샤 항중추신경계 염증제
JP5709304B2 (ja) 2011-01-06 2015-04-30 日光ケミカルズ株式会社 水中油型乳化化粧料
CA2812178C (en) 2011-11-17 2014-11-04 Phenomenome Discoveries Inc. Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof
EP2810079A4 (en) * 2012-01-31 2015-08-05 Teknologian Tutkimuskeskus Vtt Oy PROCESS FOR DETERMINING THE LIVERY QUANTITY OF LIQUID AND METHOD FOR DIAGNOSIS OF NAFLD
KR101639128B1 (ko) 2013-10-29 2016-07-13 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
WO2016041013A1 (en) 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
CN107080249A (zh) 2016-06-30 2017-08-22 健糖（北京）健康管理有限公司 一种供糖尿病人群食用的配方食品及其制备工艺

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, et al. Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation. 2016;134(21):1637-50.
Alshehry, Z. H., Barlow, C. K., Weir, J. M., Zhou, Y., McConville, M. J., and Meikle, P. J. (2015) An Efficient Single Phase Method for the Extraction of Plasma Lipids. Metabolites 5, 389-403
Caielli S, Banchereau J, and Pascual V. Neutrophils come of age in chronic inflammation. Curr Opin Immunol. 2012;24(6):671-7.
Dogaru, C. M., Nyffenegger, D., Pescatore, A. M., Spycher, B. D., and Kuehni, C. E. (2014) Breastfeeding and childhood asthma: systematic review and meta-analysis. Am J Epidemiol 179, 1153-1167.
Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH, Murphy RC, Jr., Raetz, CR, Russell DW, Seyama Y, Shaw W, Shimizu T, Spener F, Van Meer G, Vannieuwenhza MS, White SH, Witztum JL, and Dennis EA. A comprehensive classification system for lipids. J. Lipid Res. 2005;46:839-61.
Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, Spener F, Van Meer G, Wakelam MJ, and Dennis EA. Update of the LIPID MAPS comprehensive classification systems for lipids. J. Lipid Res. 2009;50:S9-14.
Geserick, M., Vogel, M., Gausche, R., Lipek, T., Spielau, U., Keller, E., et al. (2018) Acceleration of BMI in Early Childhood and Risk of Sustained Obesity. New England Journal of Medicine 379, 1303-1312
Gray, L. E. K., Ponsonby, A. L., Collier, F., O'Hely, M., Sly, P. D., Ranganathan, S., et al. (2019) Deserters on the atopic march: Risk factors, immune profile, and clinical outcomes of food-sensitized-tolerant infants. Allergy.
Gray, L. E. K., Ponsonby, A. L., Lin, T. X., O'Hely, M., Collier, F., Ranganathan, S., et al. (2019) High incidence of respiratory disease in Australian infants despite low rate of maternal cigarette smoking. J Paediatr Child Health 55, 1437-1444.
Hidayat, K., Du, X., and Shi, B. M. (2018) Body fatness at a young age and risks of eight types of cancer: systematic review and meta-analysis of observational studies. Obes Rev 19, 1385-1394
Huynh K, Barlow CK, Jayawardana KS, Weir JM, Mellett NA, Cinel M, et al. High-throughput plasma lipidomics: Detailed mapping of the associations with cardiometabolic risk factors. Cell Chemical Biology. 2019;26(1):71-84.
Jang, J. E., Park, H. S., Yoo, H. J., Baek, I. J., Yoon, J. E., Ko, M. S., et al. (2017) Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice. Hepatology 66, 416-431
Juonala, M., Magnussen, C. G., Berenson, G. S., Venn, A., Burns, T. L., Sabin, M. A., et al. (2011) Childhood adiposity, adult adiposity, and cardiovascular risk factors. The New England journal of medicine 365, 1876-1885
Liebisch G, Vizcaino JA, Kofeler H, Trotzmuller M, Griffiths WJ, Schmitz G, Spener F, and Wakelam MJ. Shorthand notation for lipid structures derived from mass spectrometry. J. Lipid Res. 2013;54:1523-30.
Magnusson CD, Gudmundsdottir AV, and Haraldsson GG. Chemoenzymatic synthesis of a focused library of enantiopure structured 1-O-alkyl-2,3-diacyl-sn-glycerol type ether lipids. Tetrahedron. 2011;67:1821-36.
Mayer-Davis, E. J., Rifas-Shiman, S. L., Zhou, L., Hu, F. B., Colditz, G. A., and Gillman, M. W. (2006) Breast-feeding and risk for childhood obesity: does maternal diabetes or obesity status matter? Diabetes Care 29, 2231-2237.
Owen, C. G., Martin, R. M., Whincup, P. H., Smith, G. D., and Cook, D. G. (2005) Effect of infant feeding on the risk of obesity across the life course: a quantitative review of published evidence. Pediatrics 115, 1367-1377.
Paoletti R, Gotto AM, Jr., and Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(23 Suppl 1):III20-6.
Paul, S., Lancaster, G. I., and Meikle, P. J. (2019) Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease. Prog Lipid Res 74, 186-195.
Rasmiena AA, Barlow CK, Stefanovic N, Huynh K, Tan R, Sharma A, et al. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice. Atherosclerosis. 2015;243(2):598-608.
Riordan, J., and Countryman, B. A. (1980) Part I: Infant Feeding Patterns Past and Present. JOGN Nursing 9, 207
Shi Y, Dayoub W, Chen G-R, and Lemaire M. Selective synthesis of 1-O-alkyl glycerol and diglycerol ethers by reductive alkylation of alcohols. Green Chemistry. 2010;12(12).
Uwaezuoke, S. N., Eneh, C. I., and Ndu, I. K. (2017) Relationship Between Exclusive Breastfeeding and Lower Risk of Childhood Obesity: A Narrative Review of Published Evidence. Clin Med Insights Pediatr 11, 1179556517690196.
Vuillermin, P., Saffery, R., Allen, K. J., Carlin, J. B., Tang, M. L., Ranganathan, S., et al. (2015) Cohort Profile: The Barwon Infant Study. International journal of epidemiology 44, 1148-1160.
Weir JM, Wong G, Barlow CK, Greeve MA, Kowalczyk A, Almasy L, et al. Plasma lipid profiling in a large population-based cohort. J Lipid Res. 2013;54(10):2898-908.
Yu, H., Dilbaz, S., Cobmann, J., Hoang, A. C., Diedrich, V., Herwig, A., et al. (2019) Breast milk alkylglycerols sustain beige adipocytes through adipose tissue macrophages. The Journal of Clinical Investigation 129, 2485-2499.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.

Also Published As

Publication number Publication date
WO2021007623A1 (en) 2021-01-21
EP3999044A1 (en) 2022-05-25
BR112022000814A2 (pt) 2022-03-08
AU2020314798A1 (en) 2022-02-24
JP7890196B2 (ja) 2026-07-14
IL289859A (en) 2022-03-01
JP2022541277A (ja) 2022-09-22
EP3999044A4 (en) 2023-10-18
CN114502149A (zh) 2022-05-13
US20220257616A1 (en) 2022-08-18
CN120360984A (zh) 2025-07-25
CA3147249A1 (en) 2021-01-21
MX2022000664A (es) 2022-05-18

Similar Documents

Publication Publication Date Title
US20220257616A1 (en) Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject
Meng et al. Indole-3-lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine
Karachaliou et al. Biotin homeostasis and human disorders: recent findings and perspectives
Kuda et al. Docosahexaenoic acid–derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties
Sofi et al. Effects of a dairy product (pecorino cheese) naturally rich in cis-9, trans-11 conjugated linoleic acid on lipid, inflammatory and haemorheological variables: a dietary intervention study
Murakami et al. Supplemental epilactose prevents metabolic disorders through uncoupling protein-1 induction in the skeletal muscle of mice fed high-fat diets
Maas et al. Choline and polyunsaturated fatty acids in preterm infants’ maternal milk
Yang et al. Dissecting the roles of lipids in preeclampsia
Guo et al. Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study
Christinat et al. High-throughput quantitative lipidomics analysis of nonesterified fatty acids in human plasma
Fiore et al. Identification of plasma fatty acids in four lipid classes to understand energy metabolism at different levels of ketonemia in dairy cows using thin layer chromatography and gas chromatographic techniques (TLC-GC)
Cui et al. Influence of age, sex, and diet on the human fecal metabolome investigated by 1H NMR spectroscopy
t’Kindt et al. Profiling over 1500 lipids in induced lung sputum and the implications in studying lung diseases
Aumailley et al. Vitamin C modulates the metabolic and cytokine profiles, alleviates hepatic endoplasmic reticulum stress, and increases the life span of Gulo−/− mice
Al Gadban et al. Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus
Giannotti et al. A snake venom group IIA PLA2 with immunomodulatory activity induces formation of lipid droplets containing 15-d-PGJ2 in macrophages
Cajka et al. Using a lipidomics approach for nutritional phenotyping in response to a test meal containing gamma-linolenic acid
Li et al. Dietary supplementation with naringin improves systemic metabolic status and alleviates oxidative stress in transition cows via modulating adipose tissue function: a lipid perspective
Tate et al. Changes in choline metabolites and ceramides in response to a DASH-style diet in older adults
Tazuke et al. Interleukin-6 changes tight junction permeability and intracellular phospholipid content in a human enterocyte cell culture model
Bardanzellu et al. Clinical insights gained through metabolomic analysis of human breast milk
Zhao et al. Compositional Differences between Preterm Milk of Different Gestational Ages with the Term Milk: A Comparative Lipidomic Study by LC‐MS/MS
Yakah et al. Parenteral fish-oil containing lipid emulsions limit initial lipopolysaccharide-induced host immune responses in preterm pigs
Mandala et al. Reprogramming offspring liver health: maternal indole supplementation as a preventive strategy against MASLD
Bonafini et al. Possible role of CYP450 generated omega-3/omega-6 PUFA metabolites in the modulation of blood pressure and vascular function in obese children

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000